腦功能生物標記科技

NeuraLight, a health technology company specializing in precision brain function biomarkers derived from eye movements, has announced that its platform will be integrated into the Healthy Brain Ageing (HeBA) initiative, a large-scale European study spanning Germany, Austria, Spain, and Luxembourg that has enrolled nearly 13,000 adults aged 50 to 80. This research venture is supported by The Michael J. Fox Foundation.

NeuraLight's goal is to identify developing Parkinson's disease up to a decade before clinical symptoms manifest. The collaboration adds NeuraLight's quantitative, scalable measures of neural circuit function — which are governed by distributed brain networks and can detect subtle changes not readily captured by conventional clinical scales — to Healthy Brain Ageing's existing gold-standard biological and clinical assessments, thereby enhancing the study's ability to track functional decline over time and distinguish early pathological changes from normal aging.